In vitro and in vivo preclinical testing of pericyte-engineered grafts for correction of congenital heart defects

用于矫正先天性心脏缺陷的周细胞工程移植物的体外和体内临床前测试

• 批准号: MR/N027086/1
• 负责人: Paolo Madeddu
• 金额: $ 79.35万
• 依托单位: University of Bristol
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FN027086%2F1
• 关键词: vitro; vivo; preclinical; testing; pericyte

Congenital heart disease (CHD) is the most common type of birth defect, with a reported prevalence ranging from 6 to 13 per 1,000 live births. In UK alone, 4,600 babies are diagnosed with a cardiac defect each year. Despite considerable progresses in surgical techniques and medical treatments, CHD remains the first cause of mortality associated with a congenital defect. In addition, the material used by cardiac surgeons to correct cardiac defects has limited durability. Hence, patients are grown through repeated risky operations. We propose a definitive solution which is based on the incorporation of patient's own stem cells in grafts currently used to correct cardiac defects. Stem cells shall confer the graft with capability to grow and adapt to the need of the young heart. We will initially work to set up the protocol for optimal incorporation of cells in the graft and then test the therapeutic activity of the new grafts in animal models, in view of a therapeutic application in CHD patients.

先天性心脏病(CHD)是最常见的出生缺陷类型，报告的患病率为每1000名活产儿中有6至13人。仅在英国，每年就有4600名婴儿被诊断出患有心脏缺陷。尽管外科技术和医疗治疗取得了长足的进步，但CHD仍然是与先天性缺陷相关的第一大死亡原因。此外，心脏外科医生用来矫正心脏缺陷的材料耐用性有限。因此，患者是通过反复的高风险手术成长起来的。我们提出了一个最终的解决方案，这是基于将患者自己的干细胞整合到目前用于纠正心脏缺陷的移植物中。干细胞将赋予移植物生长和适应年轻心脏需求的能力。我们将首先建立细胞在移植物中的最佳整合方案，然后在动物模型中测试新移植物的治疗活性，以期在冠心病患者中应用。

项目成果

Pericyte Seeded Dual Peptide Scaffold with Improved Endothelialization for Vascular Graft Tissue Engineering.

• DOI: 10.1002/adhm.201600699
• 发表时间: 2016-12
• 期刊: Advanced healthcare materials
• 影响因子: 10
• 作者: Campagnolo P;Gormley AJ;Chow LW;Guex AG;Parmar PA;Puetzer JL;Steele JA;Breant A;Madeddu P;Stevens MM
• 通讯作者: Stevens MM

In Vitro and In Vivo Preclinical Testing of Pericyte-Engineered Grafts for the Correction of Congenital Heart Defects

• DOI: 10.1161/jaha.119.014214
• 发表时间: 2020-02-18
• 期刊: JOURNAL OF THE AMERICAN HEART ASSOCIATION
• 影响因子: 5.4
• 作者: Alvino, Valeria Vincenza;Kilcooley, Michael;Madeddu, Paolo
• 通讯作者: Madeddu, Paolo

Current Strategies for the Manufacture of Small Size Tissue Engineering Vascular Grafts.

• DOI: 10.3389/fbioe.2018.00041
• 发表时间: 2018
• 期刊: Frontiers in bioengineering and biotechnology
• 影响因子: 5.7
• 作者: Carrabba M;Madeddu P
• 通讯作者: Madeddu P

Perivascular cells and tissue engineering: Current applications and untapped potential.

• DOI: 10.1016/j.pharmthera.2016.11.002
• 发表时间: 2017-03
• 期刊: Pharmacology & therapeutics
• 影响因子: 13.5
• 作者: Avolio E;Alvino VV;Ghorbel MT;Campagnolo P
• 通讯作者: Campagnolo P